The role of different genetic subtypes of CEBPA mutated AML.
about
Acute Myeloid Leukemia: A Concise ReviewGenomics-based Approach and Prognostic Stratification Significance of Gene Mutations in Intermediate-risk Acute Myeloid LeukemiaPrognostic implications of CEBPA mutations in pediatric acute myeloid leukemia: a report from the Japanese Pediatric Leukemia/Lymphoma Study GroupPharmacological targeting of the Wdr5-MLL interaction in C/EBPα N-terminal leukemia.Novel Prognostic and Therapeutic Mutations in Acute Myeloid LeukemiaClonal hematopoiesis and blood-cancer risk inferred from blood DNA sequenceDouble CEBPA mutations are prognostically favorable in non-M3 acute myeloid leukemia patients with wild-type NPM1 and FLT3-ITD.The multifaceted functions of C/EBPα in normal and malignant haematopoiesis.Mitogen-activated protein kinase binding protein 1 (MAPKBP1) is an unfavorable prognostic biomarker in cytogenetically normal acute myeloid leukemia.Identification of somatic mutations using whole-exome sequencing in Korean patients with acute myeloid leukemiaAcute myeloid leukemia in the era of precision medicine: recent advances in diagnostic classification and risk stratification.The value of molecular stratification for CEBPA(DM) and NPM1(MUT) FLT3(WT) genotypes in older patients with acute myeloid leukaemiaThe potential of a single enhancerWhole exome sequencing reveals a C-terminal germline variant in CEBPA-associated acute myeloid leukemia: 45-year follow up of a large family.Minimal residual disease testing in hematologic malignancies and solid cancer.Diagnosing and following adult patients with acute myeloid leukaemia in the genomic age.Normal karyotype acute myeloid leukemia patients with CEBPA double mutation have a favorable prognosis but no survival benefit from allogeneic stem cell transplant.The diagnostic and clinical impact of genetics and epigenetics in acute myeloid leukemia.Effects of Mesenchymal Stem Cell Derivatives on Hematopoiesis and Hematopoietic Stem Cells.Targeting human SET1/MLL family of proteins.Myelodysplastic syndromes and acute leukemia with genetic predispositions: a new challenge for hematologists.Acute myeloid leukaemia genomics.C/EBPα deregulation as a paradigm for leukemogenesis.The presence of C/EBPα and its degradation are both required for TRIB2-mediated leukaemia.The applicability of the WHO classification in paediatric AML. A NOPHO-AML study.Gene mutational pattern and expression level in 560 acute myeloid leukemia patients and their clinical relevance.MiRNAs and piRNAs from bone marrow mesenchymal stem cell extracellular vesicles induce cell survival and inhibit cell differentiation of cord blood hematopoietic stem cells: a new insight in transplantationGenetic analysis of five children with essential thrombocytosis identified mutations in cancer-associated genes with roles in transcriptional regulation.Collaborating constitutive and somatic genetic events in myeloid malignancies: ASXL1 mutations in patients with germline GATA2 mutations.Variable outcome and methylation status according to CEBPA mutant type in double-mutated acute myeloid leukemia patients and the possible implications for treatment.Emerging molecular predictive and prognostic factors in acute myeloid leukemia.Fanconi Anemia germline variants as susceptibility factors in aplastic anemia, MDS and AML.Molecular Analysis of Gene Rearrangements and Mutations in Acute Leukemias and Myeloid Neoplasms.Subtype-specific patterns of molecular mutations in acute myeloid leukemia.Mutational spectrum of acute myeloid leukemia patients with double CEBPA mutations based on next-generation sequencing and its prognostic significance.Genetic heterogeneity of cytogenetically normal AML with mutations of
P2860
Q26766719-61931AAD-9FB4-41B8-9ADE-55AE1B79984EQ26796514-3B53EAEE-E989-4F6D-A4A7-1FF8DF1EB9AEQ27853039-8C49F7E9-1628-4EC0-8232-B34D7A50502FQ27853186-0EC0B9F0-3691-4C0B-AC33-8B4C1299EB09Q28075654-32857CBD-7BF9-4956-AD0B-F6B1E7FE692AQ28385712-0FB1176E-3DA6-4855-9034-E902369970B5Q34502042-6C653805-27C0-48F1-B4B0-83F4363AF815Q34502869-A6BBDF53-007C-4055-BF2B-D9FB4442F9A0Q35781530-B07AE350-8234-400C-928C-2F370DD3A6DDQ36294464-AA83F50C-A079-43D7-B919-ABA4F617A869Q36849666-9DA6F3AC-CF2E-4826-B940-4C1073265FF8Q36866323-B94ACCCB-1093-46D9-9973-6B11CF2066F7Q37015672-837707A7-8B0E-4458-BF51-CD5EBC7690D9Q37216459-2C5CDA88-131C-4E6E-BBCC-DEA90374BA77Q38220970-25DAAA53-F931-447C-9163-8C5643691A0AQ38240563-FBB9959F-15B0-4CA1-8063-8423DC8A10C4Q38420779-462D669A-1A27-426D-891C-4F7EC42601A1Q38482005-C94D05A5-B590-48C5-BC24-D951EB9F2BB5Q38648911-AEB5B627-DF1B-475C-A880-CE3E6EE6A391Q38979643-D7BF98EC-0368-4E82-B40D-9D7433AD0EF0Q39000607-1D835E5C-26ED-4DAF-9B80-04451677CB45Q39400164-5F52560D-03F0-4ED8-AC65-444936DF74D5Q39442731-19CEC3C8-818B-4A35-9A04-B2215C74B137Q39903788-951A0786-4E24-43CA-A385-B7AD43F66465Q41144841-FA61E1B1-A79C-4B1C-94AB-D84222100D54Q41498838-8A57E598-5C3C-4FBA-88FC-9632601D2664Q42069315-87F89AEE-996F-4378-8DA1-4A1AB15FA82FQ42397458-FE14ED5C-DB3B-4A06-A390-F542996CB4F5Q42633067-3B35D569-AECC-40EC-A548-4003031DF3EAQ47660404-4D37DC5B-79B5-4C81-9EFA-D68C14EA6923Q47670541-60FCAB62-8605-457B-995D-5ADF834B619DQ50128012-5C6122E7-8A86-41F4-B7DC-45F64866C832Q51200437-6FAB96B2-A013-4A27-A6BE-78791E7E7326Q53085977-FBC8AE12-6A74-41F4-B1D6-70BE23D46AEFQ55020301-4C38FAD0-20EF-4B6F-AB36-1B0C6657B099Q57795864-65DAB386-807A-4EDC-978B-8B0E5AD7FE04
P2860
The role of different genetic subtypes of CEBPA mutated AML.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
The role of different genetic subtypes of CEBPA mutated AML.
@en
The role of different genetic subtypes of CEBPA mutated AML.
@nl
type
label
The role of different genetic subtypes of CEBPA mutated AML.
@en
The role of different genetic subtypes of CEBPA mutated AML.
@nl
prefLabel
The role of different genetic subtypes of CEBPA mutated AML.
@en
The role of different genetic subtypes of CEBPA mutated AML.
@nl
P2093
P356
P1433
P1476
The role of different genetic subtypes of CEBPA mutated AML.
@en
P2093
A Kohlmann
S Schindela
S Schnittger
S Weissmann
T Alpermann
V Grossmann
P2888
P304
P356
10.1038/LEU.2013.273
P577
2013-09-23T00:00:00Z
P6179
1019677581